Part three of the three part post: cure versus control.

Regular readers will likely remember that I take part, time to time, in a series of panels on Myeloma hosted by the wonderful people at Cure Talk, with help from Priya Menon who has done a remarkable job of assembling this program.

At 5PM Eastern on February 26th, there will be a panel discussing “Cure vs. Control” and featuring noted Myeloma expert Dr. S. Vincent Rajkumar of Mayo, Rochester.

This is of particular interest to me for two reasons.  First, Dr. Rajkumar took part in a very thoughtful debate with my doctor a few years ago, and this debate can be found on youtube here (this is part 1 of 4).   I’m looking forward to learning if Dr. Rajkumar, in light of the progress made in the last two years and the announcement of the Black Swan initiative by the IMF, has reconsidered his stance that the disease is not curable.

Second, and probably more important to me personally, is that Dr. Rajkumar was the author of the paper that discussed the presence of transient monoclonal protein after transplant being a good thing.  I’m interested in learning why we are just now observing this (when for years we knew that oligoclonal bands appear during immune system recovery), what difference if any there is between the two types of bands appearing post-treatment, and what impact it this might have on assessing the effectiveness of treatment.   Since I exhibited both oligoclonal and — much later — monoclonal bands during recovery, I’m particularly intrigued.

For instructions on how to participate on the call, including the opportunity to ask a question of the panel or Dr. Rajkumar, click here.

You can also post a comment here with a question for me to ask the good doctor!